Franziska Blaeschke, MD, PhD
Collaborator
Business Service Ctr
Chancellor/EVC/FAS

Publications (36)

Top publication keywords:
CD28 AntigensProgrammed Cell Death 1 ReceptorPrecursor B-Cell Lymphoblastic Leukemia-LymphomaCRISPR-Cas SystemsT-LymphocytesCD8-Positive T-LymphocytesReceptors, Antigen, T-CellSarcoma, EwingImmunotherapy, AdoptiveCD4 AntigensAntigens, NeoplasmAntigens, CD19Receptors, IgECell- and Tissue-Based TherapyHepatitis A Virus Cellular Receptor 2

• AhR activation mitigates graft-versus-host disease of the central nervous system by reducing microglial NF-κB signaling.
  Blood advances 2025 Zähringer A, Morgado I, Erny D, Ingelfinger F, Gawron J, Chatterjee S, Wenger V, Schmidt D, Schwöbel L, Adams RC, Langenbach M, Hartmann A, Osswald N, Wolf J, Schlunck G, Briquez PS, Grueter K, Ruess …
• Advances in cell therapy: progress and challenges in hematological and solid tumors.
  Trends in pharmacological sciences 2024 D'Avanzo C, Blaeschke F, Lysandrou M, Ingelfinger F, Zeiser R
• Modular pooled discovery of synthetic knockin sequences to program durable cell therapies.
  Cell 2023 Blaeschke F, Chen YY, Apathy R, Daniel B, Chen AY, Chen PA, Sandor K, Zhang W, Li Z, Mowery CT, Yamamoto TN, Nyberg WA, To A, Yu R, Bueno R, Kim MC, Schmidt R, Goodman DB, Feuchtinger T, Eyquem J, …
• High-yield genome engineering in primary cells using a hybrid ssDNA repair template and small-molecule cocktails.
  Nature biotechnology 2022 Shy BR, Vykunta VS, Ha A, Talbot A, Roth TL, Nguyen DN, Pfeifer WG, Chen YY, Blaeschke F, Shifrut E, Vedova S, Mamedov MR, Chung JJ, Li H, Yu R, Wu D, Wolf J, Martin TG, Castro CE, Ye L, Esensten JH, …
• RASA2 ablation in T cells boosts antigen sensitivity and long-term function.
  Nature 2022 Carnevale J, Shifrut E, Kale N, Nyberg WA, Blaeschke F, Chen YY, Li Z, Bapat SP, Diolaiti ME, O'Leary P, Vedova S, Belk J, Daniel B, Roth TL, Bachl S, Anido AA, Prinzing B, Ibañez-Vega J, Lange S, …

Show all (31 more) Hide

• Design and Evaluation of TIM-3-CD28 Checkpoint Fusion Proteins to Improve Anti-CD19 CAR T-Cell Function.
  Frontiers in immunology 2022 Blaeschke F, Ortner E, Stenger D, Mahdawi J, Apfelbeck A, Habjan N, Weißer T, Kaeuferle T, Willier S, Kobold S, Feuchtinger T
• CRISPR activation and interference screens decode stimulation responses in primary human T cells.
  Science (New York, N.Y.) 2022 Schmidt R, Steinhart Z, Layeghi M, Freimer JW, Bueno R, Nguyen VQ, Blaeschke F, Ye CJ, Marson A
• Robust T cell activation requires an eIF3-driven burst in T cell receptor translation.
  eLife 2021 De Silva D, Ferguson L, Chin GH, Smith BE, Apathy RA, Roth TL, Blaeschke F, Kudla M, Marson A, Ingolia NT, Cate JH
• Augmenting anti-CD19 and anti-CD22 CAR T-cell function using PD-1-CD28 checkpoint fusion proteins.
  Blood cancer journal 2021 Blaeschke F, Stenger D, Apfelbeck A, Cadilha BL, Benmebarek MR, Mahdawi J, Ortner E, Lepenies M, Habjan N, Rataj F, Willier S, Kaeuferle T, Majzner RG, Busch DH, Kobold S, Feuchtinger T
• Targeted delivery of CRISPR-Cas9 and transgenes enables complex immune cell engineering.
  Cell reports 2021 Hamilton JR, Tsuchida CA, Nguyen DN, Shy BR, McGarrigle ER, Sandoval Espinoza CR, Carr D, Blaeschke F, Marson A, Doudna JA
• Protective T cell receptor identification for orthotopic reprogramming of immunity in refractory virus infections.
  Molecular therapy : the journal of the American Society of Gene Therapy 2021 Stief TA, Kaeuferle T, Müller TR, Döring M, Jablonowski LM, Schober K, Feucht J, Dennehy KM, Willier S, Blaeschke F, Handgretinger R, Lang P, Busch DH, Feuchtinger T
• CLEC12A and CD33 coexpression as a preferential target for pediatric AML combinatorial immunotherapy.
  Blood 2021 Willier S, Rothämel P, Hastreiter M, Wilhelm J, Stenger D, Blaeschke F, Rohlfs M, Kaeuferle T, Schmid I, Albert MH, Binder V, Subklewe M, Klein C, Feuchtinger T
• Anti-CD19 CARs displayed at the surface of lentiviral vector particles promote transduction of target-expressing cells.
  Molecular therapy. Methods & clinical development 2021 Cordes N, Kolbe C, Lock D, Holzer T, Althoff D, Schäfer D, Blaeschke F, Kotter B, Karitzky S, Rossig C, Cathomen T, Feuchtinger T, Bürger I, Assenmacher M, Schaser T, Kaiser AD
• TCF-1 regulates HIV-specific CD8+ T cell expansion capacity.
  JCI insight 2021 Rutishauser RL, Deguit CDT, Hiatt J, Blaeschke F, Roth TL, Wang L, Raymond KA, Starke CE, Mudd JC, Chen W, Smullin C, Matus-Nicodemos R, Hoh R, Krone M, Hecht FM, Pilcher CD, Martin JN, Koup RA, Douek…
• Endogenous TCR promotes in vivo persistence of CD19-CAR-T cells compared to a CRISPR/Cas9-mediated TCR knockout CAR.
  Blood 2020 Stenger D, Stief TA, Kaeuferle T, Willier S, Rataj F, Schober K, Vick B, Lotfi R, Wagner B, Grünewald TGP, Kobold S, Busch DH, Jeremias I, Blaeschke F, Feuchtinger T
• Leukemia escape in immune desert: intraocular relapse of pediatric pro-B-ALL during systemic control by CD19-CAR T cells.
  Journal for immunotherapy of cancer 2020 Willier S, Raedler J, Blaeschke F, Stenger D, Pazos Escudero M, Jurgeleit F, Grünewald TGP, Binder V, Schmid I, Albert MH, Wolf A, Feuchtinger T
• Rewired signaling network in T cells expressing the chimeric antigen receptor (CAR).
  The EMBO journal 2020 Dong R, Libby KA, Blaeschke F, Fuchs W, Marson A, Vale RD, Su X
• CRISPR-Cas9-Mediated Glucocorticoid Resistance in Virus-Specific T Cells for Adoptive T Cell Therapy Posttransplantation.
  Molecular therapy : the journal of the American Society of Gene Therapy 2020 Kaeuferle T, Deisenberger L, Jablonowski L, Stief TA, Blaeschke F, Willier S, Feuchtinger T
• Pooled Knockin Targeting for Genome Engineering of Cellular Immunotherapies.
  Cell 2020 Roth TL, Li PJ, Blaeschke F, Nies JF, Apathy R, Mowery C, Yu R, Nguyen MLT, Lee Y, Truong A, Hiatt J, Wu D, Nguyen DN, Goodman D, Bluestone JA, Ye CJ, Roybal K, Shifrut E, Marson A
• Leukemia-induced dysfunctional TIM-3+CD4+ bone marrow T cells increase risk of relapse in pediatric B-precursor ALL patients.
  Leukemia 2020 Blaeschke F, Willier S, Stenger D, Lepenies M, Horstmann MA, Escherich G, Zimmermann M, Rojas Ringeling F, Canzar S, Kaeuferle T, Rohlfs M, Binder V, Klein C, Feuchtinger T
• Efficacy, safety and feasibility of fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting in pediatric patients receiving moderately and highly emetogenic chemotherapy - results of a non-interventional observation study.
  BMC cancer 2019 Willier S, Cabanillas Stanchi KM, von Have M, Binder V, Blaeschke F, Feucht J, Feuchtinger T, Döring M
• Landscape of stimulation-responsive chromatin across diverse human immune cells.
  Nature genetics 2019 Calderon D, Nguyen MLT, Mezger A, Kathiria A, Müller F, Nguyen V, Lescano N, Wu B, Trombetta J, Ribado JV, Knowles DA, Gao Z, Blaeschke F, Parent AV, Burt TD, Anderson MS, Criswell LA, Greenleaf WJ, …
• Low mutational load in pediatric medulloblastoma still translates into neoantigens as targets for specific T-cell immunotherapy.
  Cytotherapy 2019 Blaeschke F, Paul MC, Schuhmann MU, Rabsteyn A, Schroeder C, Casadei N, Matthes J, Mohr C, Lotfi R, Wagner B, Kaeuferle T, Feucht J, Willier S, Handgretinger R, StevanoviC S, Lang P, Feuchtinger T
• Strategies of adoptive T -cell transfer to treat refractory viral infections post allogeneic stem cell transplantation.
  Journal of hematology & oncology 2019 Kaeuferle T, Krauss R, Blaeschke F, Willier S, Feuchtinger T
• Systematic identification of cancer-specific MHC-binding peptides with RAVEN.
  Oncoimmunology 2018 Baldauf MC, Gerke JS, Kirschner A, Blaeschke F, Effenberger M, Schober K, Rubio RA, Kanaseki T, Kiran MM, Dallmayer M, Musa J, Akpolat N, Akatli AN, Rosman FC, Özen Ö, Sugita S, Hasegawa T, Sugimura H…
• Induction of a central memory and stem cell memory phenotype in functionally active CD4+ and CD8+ CAR T cells produced in an automated good manufacturing practice system for the treatment of CD19+ acute lymphoblastic leukemia.
  Cancer immunology, immunotherapy : CII 2018 Blaeschke F, Stenger D, Kaeuferle T, Willier S, Lotfi R, Kaiser AD, Assenmacher M, Döring M, Feucht J, Feuchtinger T
• MRD response in a refractory paediatric T-ALL patient through anti-programmed cell death 1 (PD-1) Ab treatment associated with induction of fatal GvHD.
  Bone marrow transplantation 2017 Boekstegers AM, Blaeschke F, Schmid I, Wiebking V, Immler S, Hoffmann F, Bochmann K, Müller S, Grünewald TGP, Feucht J, Feuchtinger T
• Posaconazole plasma concentrations in pediatric patients receiving antifungal prophylaxis during neutropenia.
  Medical mycology 2017 Döring M, Cabanillas Stanchi KM, Klinker H, Eikemeier M, Feucht J, Blaeschke F, Schwarze CP, Ebinger M, Feuchtinger T, Handgretinger R, Heinz WJ
• Ewing sarcoma partial regression without GvHD by chondromodulin-I/HLA-A*02:01-specific allorestricted T cell receptor transgenic T cells.
  Oncoimmunology 2017 Thiel U, Schober SJ, Einspieler I, Kirschner A, Thiede M, Schirmer D, Gall K, Blaeschke F, Schmidt O, Jabar S, Ranft A, Alba Rubío R, Dirksen U, Grunewald TGP, Sorensen PH, Richter GHS, von Lüttichau …
• Efficacy, safety and feasibility of antifungal prophylaxis with posaconazole tablet in paediatric patients after haematopoietic stem cell transplantation.
  Journal of cancer research and clinical oncology 2017 Döring M, Cabanillas Stanchi KM, Queudeville M, Feucht J, Blaeschke F, Schlegel P, Feuchtinger T, Lang P, Müller I, Handgretinger R, Heinz WJ
• T-cell responses against CD19+ pediatric acute lymphoblastic leukemia mediated by bispecific T-cell engager (BiTE) are regulated contrarily by PD-L1 and CD80/CD86 on leukemic blasts.
  Oncotarget 2016 Feucht J, Kayser S, Gorodezki D, Hamieh M, Döring M, Blaeschke F, Schlegel P, Bösmüller H, Quintanilla-Fend L, Ebinger M, Lang P, Handgretinger R, Feuchtinger T
• Bone marrow involvement identifies a subgroup of advanced Ewing sarcoma patients with fatal outcome irrespective of therapy in contrast to curable patients with multiple bone metastases but unaffected marrow.
  Oncotarget 2016 Thiel U, Wawer A, von Luettichau I, Bender HU, Blaeschke F, Grunewald TG, Steinborn M, Röper B, Bonig H, Klingebiel T, Bader P, Koscielniak E, Paulussen M, Dirksen U, Juergens H, Kolb HJ, Burdach SE
• Lysosome-associated membrane glycoprotein 1 predicts fratricide amongst T cell receptor transgenic CD8+ T cells directed against tumor-associated antigens.
  Oncotarget 2016 Kirschner A, Thiede M, Blaeschke F, Richter GH, Gerke JS, Baldauf MC, Grünewald TG, Busch DH, Burdach S, Thiel U
• Human HLA-A*02:01/CHM1+ allo-restricted T cell receptor transgenic CD8+ T cells specifically inhibit Ewing sarcoma growth in vitro and in vivo.
  Oncotarget 2016 Blaeschke F, Thiel U, Kirschner A, Thiede M, Rubio RA, Schirmer D, Kirchner T, Mall S, Klar R, Riddell S, Busch DH, Krackhardt A, Grunewald TG, Burdach S
• Allogeneic stem cell transplantation for patients with advanced rhabdomyosarcoma: a retrospective assessment.
  British journal of cancer 2013 Thiel U, Koscielniak E, Blaeschke F, Grunewald TG, Badoglio M, Diaz MA, Paillard C, Prete A, Ussowicz M, Lang P, Fagioli F, Lutz P, Ehninger G, Schneider P, Santucci A, Bader P, Gruhn B, Faraci M, …
• Human leukocyte antigen distribution in German Caucasians with advanced Ewing's sarcoma.
  Klinische Padiatrie 2012 Thiel U, Wolf P, Wawer A, Blaeschke F, Grunewald TG, von Lüttichau IT, Klingebiel T, Bader P, Borkhardt A, Laws HJ, Handgretinger R, Lang P, Schlegel PG, Eyrich M, Gruhn B, Ehninger G, Koscielniak E, …